Navigation Links
RNL BIO, a South Korean adult stem cell firm, introduces its autologous stem cell therapeutics in Turkey to treat patients with various intractable diseases
Date:9/12/2012

SEOUL, South Korea, Sept. 13, 2012 /PRNewswire/ -- RNL Bio (www.rnl.co.kr) announced on Sep 11, 2012 that it signed the agreement with RST Biomedikal Sanayi A.S. (RST), a Turkish company, to license RNL Bio's stem cell technology. Turkey is the 6th country where RNL Bio's stem cell technology has entered. This is one of the major accomplishments that RNL BIO has long focused on establishing the so-called 'Stem Cell Silk Road' with South Korean stem cell technology to give hope to patients with intractable diseases in the world.

RST as a licensee will pay the $5 million fee upfront within 60 days from the agreement and will continue to pay the running royalty of 15% of the revenue, which could be up to $ 200 million. RST will benefit from the geographical advantages of Turkey where Western, Arabic and Oriental cultures are crossed. It plans to establish a GMP facility and invite patients from Europe and Middle East early next year.

Ilknur Erdemin, CEO of RST said, "We expect to improve public health and the quality of life in Turkey through stem cell therapy technology imported from RNL BIO in treating various intractable diseases.  We will also grow Turkey to one of the world's most renowned country in regards to medical tourism with RNL's stem cell technology in combination with Turkish World's Heritage." To begin with, RST will focus on the treatment of diabetic complications, autoimmune diseases, cerebral palsy, and degenerative arthritis with RNL's autologous adipose derived stem cell technology. Stem cell therapy has already been allowed by Turkish health authority since 2011. Turkey actively promotes the industry of regenerative medicine and makes a quick move to expand in related fields. 

Dr. Jeong-Chan Ra, president of RNL Stem Cell Technology Institute said, "This licensing deal will be a good opportunity to develop RNL's stem cell technology to be the world's standards and to fulfill my goal to make RNL BIO a company that will have treated and helped the most patients suffering from intractable diseases." He had a seminar introducing his stem cell studies to Turkish attendees from related fields and distinguished invitees one day prior to signing licensing agreement.

 

 

 


'/>"/>
SOURCE RNL BIO
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Southern Research Signs Agreement with Apath, LLC to Conduct Preclinical Studies with Virus-Based HCV Screenings
2. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
3. Synteract Sponsoring and Presenting at Outsourcing in Clinical Trials Southeast Conference
4. Marken Opens Branch Office In Seoul, South Korea
5. CarePoint Partners Expands Coverage in Southeast
6. CPhI South America 2012 Returns to Brazil with One of a Kind Pharma Event
7. Albemarle expands South Haven API production site
8. Medical Oncology Association of Southern California Purchasing Network (MPN) Names Cardinal Health Specialty Solutions as its Primary Healthcare Solutions Partner
9. Sanford Wittels & Heisler Files $100 Million Gender Discrimination Class Action In Southern District Of New York
10. South Carolinas Stop-Sale System Achieves Significant Results In Battle Against Meth
11. Arthritis Associates of South Florida Acquires Access to Patient Health History Faster with Digital Pen Technology from Anoto and NextGen Healthcare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
Breaking Medicine News(10 mins):